| Target- | 
| Mechanism- | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
|  | 
| MechanismMAGEA3 inhibitors | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
|  | 
| MechanismKRAS G12V inhibitors | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
 / Unknown statusEarly Phase 1IIT To Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of T Cell Receptor T Cell Therapy in the Treatment of Advanced Pancreatic Cancer
To investigate the safety, tolerability, efficacy and pharmacokinetics of TCR-T cells in the treatment of advanced pancreatic cancer
100 Clinical Results associated with Shanghai Essight Bio Co.,Ltd
0  Patents (Medical) associated with Shanghai Essight Bio Co.,Ltd
100 Deals associated with Shanghai Essight Bio Co.,Ltd
100 Translational Medicine associated with Shanghai Essight Bio Co.,Ltd